BHC

Bausch Health Companies Inc.

$8.29

-1.31%

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Source: Yahoo Finance
AI summary

Price & performance

1M+40.7%
3M+36.0%
YTD+13.7%
1Y+24.1%
52-week range—
Beta0.98
Full chart and returns against a benchmark

Q-Score

64/ 100

Quality against peers; 50 is the peer median.

Growth54
Risk61
Performance50
Valuation78
Profitability67
Leverage52
Sentiment33
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$10.3B+6.7%
Net income$157M
Net margin1.5%+2.0 pts
Historical fundamentals

Revenue exposure

40%of revenue from outside the US
United Statesand Puerto Rico60%
Other Countries11%
China5%
Largest customer18%
Regions, segments, customers and suppliers

Valuation

BHCIndustryP/E—35.25P/S0.282.74EV/EBITDA8.8716.35P/B—2.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Oct 28next report, after the close
EPS estimate$1.24
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate